Top

Published in:

01-10-2023 | Ruxolitinib | Case report

Nirmatrelvir+ritonavir/ruxolitinib interaction

Tumour lysis syndrome following drug interaction and off-label use: case report

Author Information

An event is serious (based on the ICH definition) when the patient outcome is: Drug interaction

…

Country of occurrence, reporter country and primary source country not stated. Abstract presented at Chest 2023.

SINGH J, et al. TUMOR LYSIS SYNDROME DUE TO CONCURRENT ADMINISTRATION OF PAXLOVID AND RUXOLITINIB. Chest 164 (Suppl.): A2774-A2775, No. 4, Oct 2023. Available from: URL: http://doi.org/10.1016/j.chest.2023.07.1829 [abstract]

Title: Nirmatrelvir+ritonavir/ruxolitinib interaction
Tumour lysis syndrome following drug interaction and off-label use: case report
Publication date: 01-10-2023
Publisher: Springer International Publishing
Keywords: Ruxolitinib
Ritonavir
Acute Kidney Injury
Acute Kidney Injury
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-48509-1